Monitor Biogen's upcoming full earnings release for confirmation of the $34 million charge and any additional financial details. The preliminary nature of this filing means final results could differ.
BIIB drugs
BIIB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $172.25entry
- T+1 · 7mo ago +1.95%α +1.89% · $175.61
- T+5 · 7mo ago +2.03%α −2.11% · $175.74
- T+20 · 7mo ago +8.33%α −0.65% · $186.60
- T+60 · 5mo ago +21.77%α +8.59% · $209.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Biogen issued a preliminary earnings update for Q1 2026, expecting a $34 million charge for acquired in-process R&D and milestone expenses, impacting EPS by approximately $0.19 per share. This is a forward-looking estimate ahead of final results.
Key Facts
- Biogen expects a $34 million pre-tax charge for acquired in-process R&D, upfront, and milestone expenses in Q1 2026.
- The charge is expected to reduce both GAAP and non-GAAP diluted EPS by approximately $0.19 per share.
- Final results for Q1 2026 are not yet finalized and remain subject to closing procedures.
Financial Impact
Approximately $34 million pre-tax charge, reducing EPS by $0.19 per share
Risk Factors
- Final financial results may differ from these preliminary estimates.
- The R&D charge could be larger or smaller than expected based on final accounting.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000875045-26-000039 |
| Document: 0000875045-26-000039-index-headers.html | 0000875045-26-000039 |
| Document: 0000875045-26-000039-index.html | 0000875045-26-000039 |
| Document: 0000875045-26-000039.txt | 0000875045-26-000039 |
| 8-K Data (Synthetic) | 0000875045-26-000039 |
Track record
34 reports on BIIB
10 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
- Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
- Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
- Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
- Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers